Humana Inc. (NYSE:HUM) Stock Holdings Lifted by abrdn plc

abrdn plc raised its position in Humana Inc. (NYSE:HUMFree Report) by 123.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,600 shares of the insurance provider’s stock after purchasing an additional 106,586 shares during the quarter. abrdn plc’s holdings in Humana were worth $88,174,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HUM. Vantage Investment Partners LLC boosted its stake in Humana by 46.3% during the 4th quarter. Vantage Investment Partners LLC now owns 15,599 shares of the insurance provider’s stock valued at $7,141,000 after purchasing an additional 4,937 shares during the period. HTLF Bank acquired a new position in Humana in the 4th quarter valued at approximately $381,000. Fidelis Capital Partners LLC raised its holdings in Humana by 16.9% in the 4th quarter. Fidelis Capital Partners LLC now owns 1,002 shares of the insurance provider’s stock valued at $459,000 after acquiring an additional 145 shares in the last quarter. Calamos Advisors LLC raised its holdings in Humana by 8.8% in the 4th quarter. Calamos Advisors LLC now owns 76,948 shares of the insurance provider’s stock valued at $35,228,000 after acquiring an additional 6,207 shares in the last quarter. Finally, Wright Investors Service Inc. acquired a new position in Humana in the 4th quarter valued at approximately $494,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.32% of the company’s stock.

Humana Stock Up 1.1 %

NYSE HUM opened at $328.33 on Friday. The firm has a market cap of $39.61 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. The stock’s 50 day simple moving average is $330.40 and its 200 day simple moving average is $400.22. Humana Inc. has a one year low of $299.23 and a one year high of $541.21.

Humana (NYSE:HUMGet Free Report) last announced its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The firm had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm’s quarterly revenue was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.62 earnings per share. As a group, sell-side analysts forecast that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.08%. Humana’s payout ratio is 17.86%.

Analyst Ratings Changes

HUM has been the subject of several recent research reports. Argus cut Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Mizuho cut their price target on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a report on Friday, January 26th. Raymond James started coverage on Humana in a report on Friday, March 22nd. They issued a “market perform” rating for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $391.00 target price on shares of Humana in a report on Wednesday, April 10th. Finally, Wells Fargo & Company dropped their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Humana has a consensus rating of “Hold” and a consensus target price of $465.42.

View Our Latest Analysis on Humana

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.